Please click here to log in with you RCPsych web account details; you will be redirected back to CPD Online.If you have forgotten your College web account details, you will be able to reset them here.
Please click here to log in if your institution has a subscription to CPD Online with Athens access.
Please click here to log in if you are subscribed through Medicom Netherlands.
If you having troubles signing in with the options above, please try this alternative login route.
by Dr Matthew Goldin and Dr Jenny Bearn
Published: June 2013
Gamma-hydroxybutyrate (GHB) is an endogenous brain compound. In pharmacological doses it is a rapidly acting central nervous system depressant.
Although in the past GHB has been used for various clinical reasons, its recreational use is now increasing (along with the use of its precursors, gamma-butyrolactone and 1,4-butanediol). Medical literature reports rising cases of GHB intoxication, dependence and severe withdrawal, which are potentially fatal, and the clinical effects of the drug can be unpredictable and difficult to diagnose.
This module outlines the history, epidemiology and pharmacology of GHB, and provides a summary of the medico-legal issues associated with the drug. By the end of the module you should be able to recognise the clinical features of GHB intoxication, dependence and withdrawal, and be aware of the clinical management options available.
Start the module
If you like this module, you may also be interested in:
Buprenorphine in opioid dependence by Dr Lucinda M. Cockayne and Ms Elizabeth Hutchings
Stimulants: epidemiology and impact on mental health by Professor Fabrizio Schifano and Dr Antonio Albanese
Stimulants: treatment approaches and organising services by Professor Fabrizio Schifano and Dr Antonio Albanese
Drug Misuse: Psychosocial Interventions – The NICE Guideline (book from RCPsych Publications)
Download take-home notes to print and annotate